System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

David Mischoulon is an expert in Psychiatry at Massachusetts General Hospital (United States). As of October 2026, ScienceLeadR ranks David Mischoulon in the top 1% of experts worldwide for Depressive Disorder, Mood Disorders and depressive disorder, major. David Mischoulon has authored 388 publications, the most recent in 2026, and is an investigator in 33 clinical trials, 4 of them ongoing. SLR score: 1,216 (community average: 125). How the SLR is computed.

LeadR Profile

David Mischoulon Massachusetts General Hospital United States
1 216 ScienceLeadR Reputation 1216

Unlock

Register Login
Network Map

Psychiatry

Subspecialties: Geriatrics - Neurology - Psychology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026
Source: PubMed

Massachusetts General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 388

Citations

Citations: 15 667 1st author: 42 Last author: 65 Unique author: 14

Main journals

J Affect Disord 39
J Clin Psychiatry 36
Eur Neuropsychopharmacol 10
J Clin Psychopharmacol 10
Biol Psychiatry 9

Best Journals

JAMA 3
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Effects of long-term daily supplementation with vitamin D3 and marine omega-3 fatty acids on change in ADRD biomarkers: A secondary analysis of a randomized clinical trial.
PMID 42746141 — research design, fatty acids, omega-3, vitamins, biomarkers, sex, cholecalciferol, fatty acids		Alzheimers Dement (N Y)20260
Moderating Effects of Stigma-related Barriers on Ethnic Identity Dimensions and Mental Health Service Utilization among Black Adults in the US.
PMID 42688760 — help-seeking behavior, aged, education, mental health, health services, mental health services		Int J Intercult Relat20250
Nutraceuticals and phytoceuticals for the treatment of major depressive disorder: a systematic review and network meta-analysis.
PMID 42680855 — antidepressive agents, bias, mental disorders, publication bias, depressive disorder, network meta-analysis, neurosciences, therapeutics, depressive disorder, major		Mol Psychiatry20261
Differentiating Bipolar Spectrum Disorders From Other Psychiatric Disorders With Shared Features: Strategies and Implications.
PMID 42161293 — mental disorders, signs and symptoms, psychiatry		Prim Care Companion CNS Disord20260
Heated yoga thaws depression: A dose-response analysis from a randomized controlled trial.
PMID 41850611 — depression, yoga, signs and symptoms, affective symptoms		J Affect Disord20260

Clinical Studies 33

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7 Study Director: 2

By phase:

N/A 16
Phase 2 6
Phase 3 6
Phase 4 4
Phase 2/Phase 3 1

By status:

Completed 27
Recruiting 3
Active not recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 33

By Monocentric/Multicentric:

monocentric 20
multicentric2to4 9
multicentric5to9 2
multicentricup10 2

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Coaching as an Adjunct to Ketamine Therapy for Treatment Resistant Depression
NCT07563868 — depression, growth, ketamine, maintenance, depressive disorder, hallucinogens, self report, mentoring, therapeutics, depressive disorder, treatment-resistant		N/ARecruiting2026
Comparing the Efficacy of Heated Yoga and Sauna as a Treatment for Depression
NCT07082998 — depression, yoga, baths, steam, steam bath, depressive disorder, mindfulness, therapeutics, depressive disorder, major		N/ARecruiting2025
Sauna for Long Covid
NCT05931497 — pilot projects, pilots, body temperature, hyperthermia, signs and symptoms, covid-19, temperature, post-acute covid-19 syndrome		N/ARecruiting2026
Specialized Pro resolving Lipid Mediators and Treatment Resistant Depression
NCT05774665 — depression, antidepressive agents, docosahexaenoic acids, soybean oil, fatty acids, omega-3, depressive disorder, therapeutics, overweight, depressive disorder, treatment-resistant, eicosapentaenoic acid, depressive disorder, major, fatty acids, lipids		Phase 2Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS